Search - tctmd.com

Displaying 1 - 20 of 85

Sort: Relevancy | Date

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Todd Neale

October 30, 2024

News Conference News PCR London Valves 2023

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

Shelley Wood

November 27, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

News Conference News CRT 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

Yael L. Maxwell

March 03, 2023

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

L.A. McKeown

September 23, 2022

News Conference News TCT 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

Caitlin E. Cox

September 19, 2022

News Conference News TCT 2022

Surgical TAVI Explants Are Risky and Rising: STS Data Carry a Warning

Shelley Wood

September 19, 2022

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

News Daily News

TAVR Yields Similar Success in Failed TAVR or Surgical Valves

Caitlin E. Cox

January 07, 2021

News Daily News

SAVR After Failed TAVR: Rare and Risky, Registry Study Finds

Yael L. Maxwell

June 10, 2020

News Conference News CRT 2020

Positive Early Data for TAVR in Low-Risk Patients With Bicuspid Valves

Michael O'Riordan

February 27, 2020

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Industry News

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

August 16, 2019

News Daily News

New TAVR NCD a ‘Missed Opportunity’ to Align SAVR, TAVR Quality

Shelley Wood

June 27, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

News Conference News TVT 2019

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

Shelley Wood

June 17, 2019

Advertisement

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

Surgical TAVI Explants Are Risky and Rising: STS Data Carry a Warning

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

TAVR Yields Similar Success in Failed TAVR or Surgical Valves

SAVR After Failed TAVR: Rare and Risky, Registry Study Finds

Positive Early Data for TAVR in Low-Risk Patients With Bicuspid Valves

FDA Expands TAVR Indication to Low-Risk Patients

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

New TAVR NCD a ‘Missed Opportunity’ to Align SAVR, TAVR Quality

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content